Purpose: We compared the upgrading rate obtained by resampling precise spots of prostate cancer (tracking biopsy) vs conventional systematic resampling during followup of men on active surveillance. Materials and Methods: From 2009 to 2017 in 352 men prostate cancer was Gleason 3 þ 3 in 268 and Gleason 3 þ 4 in 84 at initial magnetic resonance imaging-ultrasound fusion biopsy. These men subsequently underwent a second fusion biopsy. At the first biopsy session all men underwent 12-core systematic biopsies and, when magnetic resonance imaging visible lesions were present, targeted biopsies. All cancerous sites were recorded electronically. During active surveillance at a second fusion biopsy session 6 to 18 months later tracking and systematic nontracking samples were obtained. The primary outcome measure was an increase in Gleason score (upgrading) at followup sampling, which was stratified by biopsy method. Results: Overall 91 of the 352 men (25.9%) experienced upgrading at the second biopsy during a median 11-month interval. The upgrade rate in the Gleason 3 þ 3 and 3 þ 4 groups was 26.9% and 22.6%, respectively. The mean number of cores taken at second biopsy was 12.2 AE 3.3 in men with upgrading and 12.4 AE 4.1 in those who remained stable (p not significant). Men with grade 0 to 4 magnetic resonance imaging targets were all upgraded at approximately the same rate of 20% to 30% (p not significant). However, 58.8% of the men with grade 5 magnetic resonance imaging targets were upgraded. Of the 91 upgrades 48 (53%) were detected only by tracking. Conclusions: The tracking function of magnetic resonance imaging-ultrasound fusion biopsy warrants further study. When specific sites are resampled in men undergoing active surveillance of prostate cancer, upgrading is detected more often than by nontracking biopsy.
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98 j www.jurology.com 0022-5347/18/1991-0098/0 THE JOURNAL OF UROLOGY little studied. Early on an operator using 1 such device demonstrated under ideal circumstances the ability to return to the site of a prior prostate biopsy within a few mm. 2 Using ERG expression as a marker Palapattu et al recently confirmed that precise resampling of a CaP site 1 year after initial sampling is possible with an image fusion device. 3 A potential value of biopsy site tracking in men in an AS program was suggested in preliminary studies from our institution and others. 4e10 Sonn et al reported that when initial cancer core length was 4 mm or greater in a mpMRI target, more than 80% of followup tracking biopsies were also positive. 4 Felker et al reported an incremental value of serial MRI to predict the results of followup biopsy, which included tracking.
11 Frye et al found that MRI progression predicted GS upgrading in men undergoing repeat fusion biopsy, although tracking was not described. 5 In addition, GS upgrading has been detected outside MRI visible lesions. 7 Notwithstanding, to our knowledge a systematic evaluation of biopsy site tracking, including resampling tumor sites in and apart from MRI visible targets, is currently lacking.
We evaluated biopsy site tracking in a large group of men who were eligible for AS after undergoing MRI-US fusion biopsy. All men underwent a baseline 12-core systematic biopsy and when MRI visible lesions were present, they underwent targeted biopsy. Tumors were found in and apart from MRI visible lesions. All tumors were then specifically resampled by tracking biopsy during followup. The findings appear to confirm the preliminary studies that tracking biopsy provides increased detection of clinically significant CaP in men undergoing AS. Figure 1 shows the patient selection process. From the larger group of 1,141 patients in whom cancer was detected on fusion biopsy during the study period of 2009 to 2017 we eliminated 316 with GS greater than 3 þ 4 who were inappropriate candidates for AS. Also, 292 men were eliminated from study because they had received treatment, and 181 were eliminated because they had not yet undergone a second biopsy. The remaining 352 men, who were candidates for AS, represent the study sample. Of the 352 men GS 3 þ 3 was detected in 268 and GS 3 þ 4 was detected in 84 by fusion biopsy. All underwent followup fusion biopsy within 6 to 18 months. Long-term followup of a portion of these patients was reported previously.
METHODS

Study Design
8,11
The primary outcome was a Gleason score at second biopsy that was higher than at first biopsy, ie upgrading. If the initial positive fusion biopsy showed a maximum GS 3 þ 3, GS 3 þ 4 or greater on subsequent fusion biopsy was considered an upgrade. If the initial maximum GS was 3 þ 4, GS 4 þ 3 or greater was considered an upgrade.
All data collection was performed in a UCLA registry approved by the institutional review board.
Fusion Biopsy and Tracking
All biopsies were performed by a single urologist (LSM) at UCLA Clark Urology Center using the ArtemisÔ platform with the patient under local anesthesia. mpMRI and the initial fusion biopsy were done as previously described, yielding cores from the systematic (template) sites and from MRI visible lesions ( fig. 2, A) .
2,9, 12 We defined a MRI visible lesion as one classified as grade 3-5, initially using a scoring system that predates and closely approximates PI-RADS TM and later using the actual PI-RADS. 2, 13 MRIs were interpreted by 2 uroradiologists who each had more than 10 years of experience with reading prostate mpMRI. Imaging was done before the initial fusion biopsy in all 352 men and 32 with a negative MRI initially underwent repeat MRI at the time of the second biopsy. In 28 of the 32 cases a new lesion was seen. It was also sampled, which contributed 5 cases of upgrading, but sampling of new lesions did not influence the tracking analysis. At the first biopsy session each core was labeled with a specific identifier, allowing for tracking of any cancerous biopsy site that might be found.
At followup biopsy the initial prostate model, which had been saved in the Artemis device, was displayed on the work screen to show any MRI ROI and all previous biopsy sites ( fig. 2, B) . The prostate was rescanned and the initial model was fused with the second model, the overlay showing the ROI and all previous biopsy sites. Cores were then obtained from systematic sites (as initially), from any MRI visible lesions (as initially) and by resampling cancerous spots found initially (tracking). A median of 4 tracking cores (IQR 3e5) was taken from each prior area of CaP, aiming at the midpoint of each positive core and at 4-quadrant adjacent areas within 2 to 3 mm of the center point. Cancerous sites were resampled, including sites in and apart from MRI visible ROIs ( fig. 2) . A dedicated uropathologist (JH) interpreted all biopsy cores. The overall upgrade rate and the upgrade rate according to each biopsy method were determined.
Statistical Analysis
Logistic regression was used for univariate and multivariate analyses. The log rank and chi-square tests were applied to calculate p values (table 1). The exact binomial test was used to calculate CIs. Statistical significance was considered at p <0.05 in all analyses. Statistical analyses were performed with StataÒ, version 13.1. Table 1 lists baseline characteristics of the study cohort. All men in the study were candidates for AS based on GS. Of the 352 men initial biopsy revealed that 268 (76.1%) had GS 3 þ 3 CaP and 84 (23.9%) had GS 3 þ 4. Men with GS 3 þ 4 at baseline had a larger prostate, greater PSA density and longer cancer core length than men with GS 3 þ 3. Figure 1 shows patient selection and the overall upgrade rate. Overall 91 of 352 men (25.9%) experienced upgrading at second biopsy during the median 11-month interval (IQR 6e12). The upgrade rate in the GS 3 þ 3 and 3 þ 4 groups was 26.9% (95% CI 0.21e0.33) and 22.6% (95% CI 0.14e0.33), respectively. Of the upgrades in the GS 3 þ 3 group 75.0% (95% CI 0.63e0.84) were upgraded to GS 3 þ 4 while 25.0% (95% CI 0.15e0.37) were upgraded to GS greater than 3 þ 4. Of the upgrades in the GS 3 þ 4 group 47.4% (95% CI 0.24e0.71) were upgraded to GS 4 þ 3 and 52.6% (95% CI 0.29e0.76) were upgraded to GS greater than 4 þ 3.
RESULTS
Effects
Baseline Multiparametric Magnetic Resonance Imaging Grade. Table 2 shows the upgrade rate by MRI grade. Upgrading was done in 21.0% of men (95% CI 0.15e0.29) with a maximum grade 3 ROI, in 29.6% (95% CI 0.20e0.41) with grade 4 upgraded and in 58.8% (95% CI 0.33e0.81) with grade 5 upgraded.
Of the 352 men 116 (32.7%) initially did not have MRI visible targets. Of the 116 men with initially negative mpMRI 32 underwent repeat mpMRI before the second biopsy because of increased clinical suspicion, and upgrading was noted in 28 (24.1%, 95% CI 0.17e0.33). Four of the 28 upgrades (14.2%) in this group were missed by systematic tracking but found by target biopsy of a ROI seen on the second mpMRI. One of the 28 upgrades (3.6%) was missed by systematic tracking but found by nontracked systematic sites (data not shown). Two upgrades were found by multiple Figure 1 . How patients were selected for study. Second biopsy contained no cancer (GS 0) in 28% of men with GS 6 and 14% with GS 7 even with targeting. These men may represent especially low risk group.
methods. The remaining 21 upgrades (75.0%) were found only by systematic tracking biopsy. Stated otherwise, three-quarters of the upgrades in men with no MRI visible lesion were found only by tracking a cancer focus present on a template site at initial sampling.
Sampling Method. Table 3 shows the rates of cancer detection based on sampling method at the first and second biopsy sessions. At the first session 268 men were diagnosed with GS 3 þ 3, including 175 by systematic biopsy only, 41 by target biopsy only and 52 by systematic as well as target biopsy. The upgrade rate in these groups was 24.6%, 31.7% and 30.8%, respectively. A total of 84 men were diagnosed with GS 3 þ 4, including 53 by systematic biopsy only, 28 by targeted biopsy only and 3 by the 2 types. The upgrade rate based on these groupings was 18.9%, 25.0% and 66.7%, respectively. In each group MRI visible lesions were more likely to contain tumors than other areas of the prostate. Table 3 also shows upgrades based on the second biopsy method. The 4 methods used for the second biopsy were systematic, MRI targeted, systematic tracking and MRI tracking. Figure 2 shows the 4 methods. In GS 3 þ 3 cases 41 of the 72 upgrades (56.9%, 95% CI 0.45e0.69) were found by tracking (systematic tracking and/or MRI target tracking) but missed by nontracking (systematic and/or MRI targeted). Of the upgrades 17 (23.6%, 95% CI, 0.14e0.35) found by nontracking were missed by tracking. Differences were less pronounced in the GS 3 þ 4 groups, in which the number was small. Overall when combining the GS groups, 48 of 91 upgrades (52.7%, 95% CI, 0.42e0.63) were found by tracking only. Regarding the total number of cores obtained at second biopsy, no significant difference was found between men with an upgraded GS vs those with a stable GS (mean AE SD 12.2 AE 3.3 vs 12.4 AE 4.1). Figure 3 , which combines the GS 3 þ 3 and 3 þ 4 groups, shows the number of upgrades based on the 4 repeat biopsy methods. The upgrade rate was 7.3% (95% CI 0.04e0.14), 15.4% (95% CI 0.11e0.21), 17.1% (95% CI 0.13e0.22) and 30.2% (95% CI 0.21e0.40) based on systematic, MRI targeted, systematic tracking and MRI tracking biopsies, respectively. Table 4 shows univariate analysis. In initial GS 3 þ 3 cases PSA density and a greater number of positive cores on first biopsy were associated with upgrading (each p ¼ 0.001). Prostate volume remained unchanged (p not significant) and it was not predictive of upgrading. In initial GS 3 þ 4 cases none of the variables predicted an upgrade.
Univariate and Multivariate Analyses
On multivariate analysis of GS 3 þ 3 cases upgrading was associated with PSA density Figure 2 . Examples of biopsy methods. A, first biopsy consisted of 12 systematic cores (green symbols) following built-in template and targeted cores (yellow symbols) taken from the MRI visible lesion (dotted line). B, second biopsy, which shows preliminary fusion of first and second prostate models, consisted of systematic cores (green symbols), MRI targeted cores (yellow symbols) and tracking cores from systematic cancer sites (blue symbols) or cancerous sites in MRI lesions (red symbols). Using this scheme all initial cancerous sites were resampled in and apart from MRI visible lesions. 
DISCUSSION
Before image fusion devices were available tracking prostate cancer foci was inexact because a practical mechanism to record biopsy sites did not exist. Han et al found that when using US alone, even skilled and experienced urologists were often unable to match the planned core location to the actual site to be sampled in the prostate. 14 With the advent of image fusion devices recording and later resampling specific sites containing tumor foci became possible.
5,15,16 Some tumors are found outside MRI visible lesions or ROIs 12 but they can still be tracked. Thus, tracking may allow for the resampling of cancerous areas in the prostate irrespective of a location in or apart from a ROI. 2, 4 In men undergoing AS of CaP the benefits of tracking biopsy could be considerable.
In the current study tracking technology in the Artemis device was used to revisit and resample all tumor foci. Of the 91 cases with upgrading on the various biopsy methods 48 (53%) were detected only by tracking biopsy (table 3) . Tracking delivered a substantially higher yield than conventional systematic sampling. Of special note are the other 85 men who, despite tracking biopsy, were found to have no tumor on confirmatory biopsy ( fig. 1) . As suggested by Ganesan et al, these men may require less vigilance than men with demonstrable tumor at followup. 17 Evidence that tracking as described in this study is highly accurate was recently established using sophisticated molecular biology techniques. 3 In that series, which involved the Artemis device as in the current study, the accuracy of repeat sampling of a specific CaP clonal site during a 1-year interval was 96%. Using a different image fusion device and a panel of genes to determine resampling accuracy others reported similar findings. 18 Whether the upgrades that we report represent true progression or initial under detection could not be discerned in the current series. However, detecting the upgrades depended on tracking biopsy to a large extent.
In a large AS cohort using mostly US guided biopsy the average upgrade rate from GS 6 to GS 7 or greater on surveillance biopsy was 18.5%, 19 substantially lower than in our series. However, any comparison is complicated due to 2 reasons. 1) In the current study MRI targeting was initially done to improve screening in men who were not suitable candidates for AS. 2) Targeting was combined with tracking biopsy at the second session. Using image fusion devices to reduce sampling error via targeting and tracking, thus, increasing the detection of clinically significant cancers, appears to be a noteworthy advance.
In early studies of AS all biopsies (diagnostic, confirmatory and followup) were US guided, systematic sampling of the organ. 20, 21 The current data indicate that if the initial diagnostic biopsy is performed with an image fusion device and positive sites are tracked, resampling the previously negative systematic sites has a low yield. In our work, in which tumor was found only at a systematic site in 228 cases, a subsequent upgrade was found in a nontracked systematic site only 4 times (table 3) . Thus, resampling nontracked systematic sites (outside MRI visible lesions) may not be necessary in AS programs, allowing for a reduction in the number of cores needed at followup. In the current series biopsy tracking in MRI targets detected 30.2% of all upgrades ( fig. 2) . The importance of giving special attention to MRI visible lesions was again confirmed. However, 23 of the 93 men (24.7%) with a tumor only at a systematic site and who had no MRI visible lesions on initial biopsy were found to have upgraded disease on tracking biopsy alone. In such instances resampling systematic biopsy sites which were initially negative rarely led to the detection of upgrading (4 of 228 cases as described). Thus, tracking tumor biopsy sites enables the detection of upgrading even in men with no MRI visible lesions and it rarely misses upgrades found in those men by repeat systematic (nontracking) biopsy.
There are limitations of this study which may affect generalizability. The design was retrospective, although all data were collected in an institutional review board approved registry by following a set of protocols. MRI was interpreted by expert readers using state-of-the-art equipment, which may not be universally available. Cognitive tracking was not tested and might be of benefit, especially in small prostates. MRI-US fusion was performed by 1 urologist with extensive experience with the procedure. Also, while biopsy upgrading per se serves to heighten awareness, it may not always correlate with disease severity.
Despite these limitations the sample size was relatively large, uniform methods were used throughout the study years and the results achieved statistical significance. Tracking biopsy appears to result in increased detection of clinically significant CaP with sensitivity beyond that of conventional systematic biopsy and/or target biopsy of MRI visible lesions. Confirmation of this finding awaits a prospective, appropriately powered trial.
CONCLUSIONS
A quarter of the men who met consensus criteria for AS eligibility experienced pathological upgrading on repeat fusion biopsy. Approximately half of the upgrades were detected only by tracking biopsy. Tracking biopsy appears to add value to conventional followup biopsy in men undergoing AS for prostate cancer. This deserves further study. In this novel study the authors used tracking technology to sample prior positive sites at approximately 1-year confirmatory biopsy in 352 men enrolled in an active surveillance program at UCLA.
They report upgrading (higher Gleason score at second biopsy) in 26% of men overall. The confirmatory biopsy protocol included a modified repeat systematic biopsy in addition to sampling of all prior positive sites and MRI targets. Only 9% of men underwent repeat MRI prior to confirmatory biopsy. I found points to be particularly noteworthy. 1) The upgrading rate of about 30% is similar to the reclassification rate reported for active surveillance series using conventional TRUS biopsy.
1,2 I would have expected a lower rate of upgrading at about 1 year after initial targeted biopsy.
2) The highest yield of upgrading was achieved by resampling MRI targets that contained cancer at initial biopsy. Repeat systematic sampling of previously benign areas not associated with a MRI target had limited
